Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Ophthalmology · Pathologic Myopia

Understanding Your Diagnosis: High Myopia vs. Pathologic Myopia

At a Glance

High myopia means a very strong prescription, while pathologic or degenerative myopia means the eye has developed structural damage from stretching. They can coexist, and regular dilated eye exams and specialized scans help monitor changes before they affect vision.

Receiving a diagnosis of degenerative myopia (also known as pathologic myopia) can be an overwhelming experience. The words themselves—“degenerative” and “pathologic”—sound heavy and final, often sparking immediate anxiety about the future of your sight [1]. It is natural to feel a sense of “medical whiplash”: one day you are simply a person who wears thick glasses, and the next, you are told you have a structural disease of the eye.

This page is designed to help you navigate this transition. Understanding the difference between needing a strong prescription and having a structural eye condition is the first step in taking control of your eye health.

High Myopia vs. Pathologic Myopia

Most people are familiar with myopia (nearsightedness), where the eye is shaped in a way that makes distant objects blurry. When this nearsightedness is very strong, it is called high myopia.

However, pathologic myopia is not just “worse” nearsightedness. It is a distinct medical condition defined by physical, structural changes to the tissues inside your eye [2][3].

Feature High Myopia Pathologic Myopia
Nature A risk state defined primarily by refractive error. A structural disease (physical damage to eye tissues).
Measurement Defined by your prescription (often -6.00 diopters or stronger) or axial length [2]. Diagnosed by visible damage seen during an eye exam [3].
Cause The eyeball is typically longer than average (axial length) [2]. The eyeball has stretched so much that internal layers begin to thin or tear [3][4].
Vision Can usually be corrected to “20/20” with the right glasses or contacts, though this is not guaranteed. Vision may be limited even with the best possible glasses due to underlying tissue damage [5][6].

Note: High myopia and pathologic myopia can coexist. You can have high myopia for years before it progresses to pathologic myopia, and some people with high myopia never develop structural damage.

Why the Word “Degenerative”?

The term “degenerative” refers to the fact that the structural changes are caused by the eyeball stretching over time. As the eye grows longer, the sclera (the white outer layer), the choroid (the blood-vessel layer), and the retina (the light-sensing layer) are pulled thin [4].

When these layers stretch beyond their limit, doctors may see specific signs, such as:

  • Chorioretinal Atrophy: Areas where the tissue has thinned so much that the underlying layers are visible [7].
  • Posterior Staphyloma: A localized bulging or “stretching out” of the back of the eye [4].
  • Lacquer Cracks: Small breaks in Bruch’s membrane, a supportive layer beneath the retina [7].

It is important to know that while “degenerative” implies change, it does not mean you will lose your vision tomorrow. Many people with these structural changes maintain functional, stable vision for many years [5][8].

How Common Is This?

Pathologic myopia is relatively rare in the general population, affecting roughly 1% to 3% of adults, although estimates vary substantially by geographic population and definition [9]. However, it is much more common among people who already have high myopia.

Studies show that among people with very strong prescriptions (high myopes), approximately 32% to 42% (depending on the specific study population and age group) may show signs of myopic macular degeneration [10][11]. Because the risk increases as the eye grows longer, these changes are diagnosed more frequently in older adults, though they can begin much earlier in childhood [12][13].

Navigating the Emotional Impact

It is common for patients to feel a “loss of trust” in their eyes after this diagnosis. You may find yourself hyper-aware of every floater or flash of light. Research recognizes that anxiety is a significant component of living with high-risk eye conditions [1].

One of the most helpful ways to manage this anxiety is to move from “vague fear” to “specific knowledge.” Doctors now use a standardized classification system called META-PM to grade the type of macular damage present [7][3]. Knowing your category and your specific risks can help you and your doctor create a concrete plan for monitoring and protection.

Looking Ahead

A diagnosis of degenerative myopia changes how you and your doctor look at your eyes. Instead of just checking your prescription for new glasses, your exams will now focus on the integrity of your eye tissues.

While the structural changes cannot be “undone,” modern ophthalmology has many tools—including specialized imaging like OCT (Optical Coherence Tomography)—to monitor these changes closely and intervene if new issues arise [14][15]. Your goal is no longer just “seeing clearly” through glasses, but “protecting the health” of the eye itself.

Common questions in this guide

How is high myopia different from pathologic myopia?
High myopia is mainly a very strong prescription or a long eyeball and may be corrected well with glasses or contacts. Pathologic myopia means the stretching has caused visible structural changes in the eye, so vision may remain limited even with the best correction. The two conditions can occur together, but not everyone with high myopia develops structural damage.
Does degenerative myopia mean I will lose my sight soon?
No. The term describes structural changes caused by stretching over time, not a prediction that vision loss will happen immediately. Many people with these changes keep useful, stable vision for years, although regular monitoring is important.
What changes can doctors see in pathologic myopia?
Doctors may find chorioretinal atrophy, posterior staphyloma, or lacquer cracks. These findings reflect thinning, bulging, or small breaks in supporting tissues at the back of the eye. The exact findings and whether they affect one or both eyes should be reviewed with your ophthalmologist.
How is degenerative myopia monitored?
Monitoring may include dilated eye examinations and OCT, a scan that creates detailed images of the eye’s layers. Doctors may also use the META-PM system to describe the type and extent of macular changes. The schedule depends on your imaging and individual risk.
What visual changes should I tell my eye doctor about?
Tell your eye doctor about new or changing floaters or flashes, straight lines that look bent, or blank spots in central vision. These changes can help your doctor decide whether you need an earlier examination or additional imaging. Do not wait for a routine visit if symptoms are sudden or severe.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my imaging, which specific structural changes (like atrophy or lacquer cracks) were found?
  2. 2.Am I in a META-PM category, and if so, which one?
  3. 3.Are these changes present in both of my eyes or just one?
  4. 4.Does my current vision (best-corrected visual acuity) match the structural changes you see?
  5. 5.How often should I have dilated exams or OCT scans to monitor for new changes?
  6. 6.What is the difference between the 'atrophic' and 'active' stages, and which one applies to me right now?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Complications of high myopia: An update from clinical manifestations to underlying mechanisms.

    Du Y, Meng J, He W, et al.

    Advances in ophthalmology practice and research 2024; (4(3)):156-163 doi:10.1016/j.aopr.2024.06.003.

    PMID: 39036706
  2. 2

    IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies.

    Flitcroft DI, He M, Jonas JB, et al.

    Investigative ophthalmology & visual science 2019; (60(3)):M20-M30 doi:10.1167/iovs.18-25957.

    PMID: 30817826
  3. 3

    Updates of pathologic myopia.

    Ohno-Matsui K, Lai TY, Lai CC, Cheung CM

    Progress in retinal and eye research 2016; (52()):156-87.

    PMID: 26769165
  4. 4

    IMI Pathologic Myopia.

    Ohno-Matsui K, Wu PC, Yamashiro K, et al.

    Investigative ophthalmology & visual science 2021; (62(5)):5 doi:10.1167/iovs.62.5.5.

    PMID: 33909033
  5. 5

    Choriocapillaris Changes in Myopic Macular Degeneration.

    Li J, Zhou H, Feinstein M, et al.

    Translational vision science & technology 2022; (11(2)):37 doi:10.1167/tvst.11.2.37.

    PMID: 35201337
  6. 6

    Prevalence, Risk Factors, and Impact of Myopic Macular Degeneration on Visual Impairment and Functioning Among Adults in Singapore.

    Wong YL, Sabanayagam C, Ding Y, et al.

    Investigative ophthalmology & visual science 2018; (59(11)):4603-4613 doi:10.1167/iovs.18-24032.

    PMID: 30242361
  7. 7

    International photographic classification and grading system for myopic maculopathy.

    Ohno-Matsui K, Kawasaki R, Jonas JB, et al.

    American journal of ophthalmology 2015; (159(5)):877-83.e7.

    PMID: 25634530
  8. 8

    Absolute Risks and Decision Tools for Communicating the Risks of Visual Impairment From Myopia-Related Diseases.

    Dow E, Kearney S, Day M

    Investigative ophthalmology & visual science 2025; (66(4)):82 doi:10.1167/iovs.66.4.82.

    PMID: 40305470
  9. 9

    Epidemiology of Pathologic Myopia in Asia and Worldwide.

    Wong YL, Saw SM

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2016; (5(6)):394-402 doi:10.1097/APO.0000000000000234.

    PMID: 27898442
  10. 10

    Epidemiology of pathologic myopia in UK adults with high myopia.

    Yii F, Strang N, Bernabeu MO, et al.

    The British journal of ophthalmology 2026; (110(2)):204-211 doi:10.1136/bjo-2024-326889.

    PMID: 40854736
  11. 11

    Prevalence and Characteristics of Myopic Degeneration in an Adult Chinese American Population: The Chinese American Eye Study.

    Choudhury F, Meuer SM, Klein R, et al.

    American journal of ophthalmology 2018; (187()):34-42 doi:10.1016/j.ajo.2017.12.010.

    PMID: 29288031
  12. 12

    Differentiation Between Moderate Versus High Myopia: The 2-Continent Eye Study.

    Jonas JB, Jonas RA, Bikbov MM, et al.

    Ophthalmology science 2026; (6(2)):100999 doi:10.1016/j.xops.2025.100999.

    PMID: 41725834
  13. 13

    Prevalence of Myopic Maculopathy Among the Very Old: The Ural Very Old Study.

    Bikbov MM, Gilmanshin TR, Kazakbaeva GM, et al.

    Investigative ophthalmology & visual science 2024; (65(3)):29 doi:10.1167/iovs.65.3.29.

    PMID: 38512243
  14. 14

    Prevalence of Refractive Errors, Myopic Macular Degeneration, and Associated Risk Factors in a Maltese Population-Based Study.

    Agius D, Mamo J, Calleja N, et al.

    Clinical optometry 2026; (18()):561426 doi:10.2147/OPTO.S561426.

    PMID: 41890681
  15. 15

    Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management.

    Cheung CMG, Arnold JJ, Holz FG, et al.

    Ophthalmology 2017; (124(11)):1690-1711 doi:10.1016/j.ophtha.2017.04.028.

    PMID: 28655539

This page is for informational purposes only and does not constitute medical advice. Your ophthalmologist should interpret your imaging and set a monitoring plan for your eyes.

Get notified when new evidence is published on degenerative myopia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.